Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML

Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML

BackgroundNPM1 mutation status can influence prognosis and management in AML. Accordingly, clinical testing (i.e., RT-PCR, NGS and IHC) for mutant NPM1 is increasing in order to detect residual disease in AML, alongside flow cytometry (FC). However, the relationship of the results from RT-PCR to tra...

Full description

Bibliographic Details
Main Authors: Amanda Lopez, Sanjay Patel, Julia T. Geyer, Joelle Racchumi, Amy Chadburn, Paul Simonson, Madhu M. Ouseph, Giorgio Inghirami, Nuria Mencia-Trinchant, Monica L. Guzman, Alexandra Gomez-Arteaga, Sangmin Lee, Pinkal Desai, Ellen K. Ritchie, Gail J. Roboz, Wayne Tam, Michael J. Kluk
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
NPM1
AML
MRD
RT-PCR
NGS
IHC
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.701318/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.701318/full

Similar Items